Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sampliner

Showing results (271-280 of 290) with videos related to

Pageof 29
Sort By:
Gastroenterology|December 24, 2017
Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to NeoplasiaSravanthi Parasa, Sreekar Vennalaganti, Srinivas Gaddam, et al.
Gastroenterology|December 19, 2016
Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index EndoscopyPrashanthi N Thota, Prashanth Vennalaganti, Sreekar Vennelaganti, et al.
The New England Journal of Medicine|August 2, 1990
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy GroupR P Perrillo, E R Schiff, G L Davis, et al.
Gastroenterology|May 30, 2013
Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohortSrinivas Gaddam, Mandeep Singh, Gokulakrishnan Balasubramanian, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2013
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasiaRajeswari Anaparthy, Srinivas Gaddam, Vijay Kanakadandi, et al.
Gastrointestinal Endoscopy|October 21, 2018
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortiumMadhav Desai, David A Lieberman, Kevin F Kennedy, et al.
Journal of Clinical Gastroenterology|May 8, 2020
Low Risk of Progression of Barrett's Esophagus to Neoplasia in WomenJames E Allen, Madhav Desai, Carlijn A M Roumans, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 1, 2010
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinomaSachin Wani, Gary Falk, Matthew Hall, et al.
Endoscopy|April 25, 2015
Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort studyPreetika Sinh, Rajeswari Anaparthy, Patrick E Young, et al.
Gastroenterology|July 5, 2011
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagusSachin Wani, Gary W Falk, Jane Post, et al.
Pageof 29

Showing results (271-280 of 290) with videos related to

Sort By:
Pageof 29
Gastroenterology|December 24, 2017
Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to NeoplasiaSravanthi Parasa, Sreekar Vennalaganti, Srinivas Gaddam, et al.
Gastroenterology|December 19, 2016
Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index EndoscopyPrashanthi N Thota, Prashanth Vennalaganti, Sreekar Vennelaganti, et al.
The New England Journal of Medicine|August 2, 1990
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy GroupR P Perrillo, E R Schiff, G L Davis, et al.
Gastroenterology|May 30, 2013
Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohortSrinivas Gaddam, Mandeep Singh, Gokulakrishnan Balasubramanian, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 28, 2013
Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasiaRajeswari Anaparthy, Srinivas Gaddam, Vijay Kanakadandi, et al.
Gastrointestinal Endoscopy|October 21, 2018
Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortiumMadhav Desai, David A Lieberman, Kevin F Kennedy, et al.
Journal of Clinical Gastroenterology|May 8, 2020
Low Risk of Progression of Barrett's Esophagus to Neoplasia in WomenJames E Allen, Madhav Desai, Carlijn A M Roumans, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 1, 2010
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinomaSachin Wani, Gary Falk, Matthew Hall, et al.
Endoscopy|April 25, 2015
Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort studyPreetika Sinh, Rajeswari Anaparthy, Patrick E Young, et al.
Gastroenterology|July 5, 2011
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagusSachin Wani, Gary W Falk, Jane Post, et al.
Pageof 29